Sugi Predict

Sugi Predict / Compounds / SCHEMBL2320239

SCHEMBL2320239

SCHEMBL2320239

N#CCS(=O)(=O)c1cccc(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.42
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42
▸ CA9 Q16790 2/20 0.42
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ PGR P06401 1/20 0.40
▸ GBA1 P04062 1/20 0.39
▸ NFE2L2 Q16236 6/20 0.39
▸ KAT6A Q92794 2/20 0.38
▸ PSEN1 P49768 1/20 0.38
▸ PSEN2 P49810 1/20 0.38
▸ APH1B Q8WW43 1/20 0.38
▸ NCSTN Q92542 1/20 0.38
▸ APH1A Q96BI3 1/20 0.38
▸ PSENEN Q9NZ42 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ HDAC3 O15379 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28842239 0.98 CA12 (0.41) CA12CA1CA2CA9KMT2A
SCHEMBL17376536 0.81 EPAS1 (0.41) GBA1PSEN1PSEN2APH1BNCSTN
SCHEMBL17942342 0.79 MEN1 (0.46) CA12CA1CA2CA9KMT2A
SCHEMBL30833518 0.79 MEN1 (0.46) CA12CA1CA2CA9KMT2A
SCHEMBL2449532 0.79 ATM (0.42) KMT2AMEN1L3MBTL1PGRKAT6A
SCHEMBL7140024 0.79 KMT2A (0.50) KMT2AMEN1
SCHEMBL7951191 0.79 LMNA (0.55) CA12CA1CA2CA9KMT2A
SCHEMBL7140183 0.79 CYP1A2 (0.44) KMT2AMEN1PGRNFE2L2
SCHEMBL19707163 0.79 HSD17B1 (0.43) CA12CA1CA2CA9
SCHEMBL30583823 0.79 KMT2A (0.50) KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116675663-A Preparation method of coumarin compound and application of coumarin compound in neuroprotection 兰州交通大学 2023-09-01 — — CN claimed
CN-106488919-B 3-substituted 2-aminoindole derivatives 武田药品工业株式会社 2018-10-23 — — CN disclosed
US-10059713-B2 3-substituted 2-amino-indole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-08-28 — — US disclosed
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE TAKEDA PHARMACEUTICALS CO (JP) 2017-12-28 — — US disclosed
US-20170158700-A1 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES TAKEDA CAMBRIDGE LIMITED (GB) 2017-06-08 — — US disclosed
US-20170158700-A1 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES TAKEDA CAMBRIDGE LIMITED (GB) 2017-06-08 — — US disclosed
US-20170158700-A1 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES TAKEDA CAMBRIDGE LIMITED (GB) 2017-06-08 — — US disclosed
CN-106661032-A 1,3-substituted 2-aminoindole derivatives and analogues useful in the treatment or prevention of diabetes mellitus, obesity and inflammatory bowel disease 武田药品工业株式会社 2017-05-10 — — CN disclosed
EP-3160965-A1 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES Takeda Pharmaceutical Company Limited (JP) 2017-05-03 — — EP disclosed
EP-3160955-A1 1,3-SUBSTITUTED 2-AMINOINDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY AND INFLAMMATORY BOWEL DISEASE Takeda Pharmaceutical Company Limited (JP) 2017-05-03 — — EP disclosed
CN-106488919-A 3-substituted 2-aminoindole derivatives 武田药品工业株式会社 2017-03-08 — — CN disclosed
WO-2015198045-A1 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-30 — — WO disclosed
WO-2015198045-A1 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-30 — — WO disclosed
WO-2015198046-A1 1,3-SUBSTITUTED 2-AMINOINDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY AND INFLAMMATORY BOWEL DISEASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-30 — — WO disclosed
EP-2352725-A1 QUINOXALINE-BASED LXR MODULATORS Wyeth LLC (US) 2011-08-10 — — EP disclosed
WO-2010054229-A1 QUINOXALINE-BASED LXR MODULATORS WYETH LLC (US) 2010-05-14 — — WO disclosed
US-20100120778-A1 QUINOXALINE-BASED LXR MODULATORS WYETH (US) 2010-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE GPR119, IDO1, IDO2 CA12 4465/4885CA1 4051/4885CA2 3192/4885
US-10059713-B2 3-substituted 2-amino-indole derivatives NPY5R, XDH, NPY4R CA12 3425/4885CA1 3014/4885CA2 1822/4885
US-20100120778-A1 QUINOXALINE-BASED LXR MODULATORS NR1H2, NR1H3, NR1H4 CA12 4778/4885CA1 4367/4885CA2 4109/4885
US-20170158700-A1 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES NPY5R, XDH, NPY4R CA12 3425/4885CA1 3014/4885CA2 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.